MedPath

Timolol

Generic Name
Timolol
Brand Names
Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
Drug Type
Small Molecule
Chemical Formula
C13H24N4O3S
CAS Number
26839-75-8
Unique Ingredient Identifier
5JKY92S7BR
Background

Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

Indication

Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.

Associated Conditions
Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Clinical Trials
Related News

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 2
Completed
Conditions
Open-angle Glaucoma
Ocular Hypertension
Interventions
Drug: AL-37807 Ophthalmic Suspension, 1.0%
Drug: Latanoprost, 0.005% (Xalatan)
Other: AL-37807 Vehicle
First Posted Date
2006-02-07
Last Posted Date
2012-03-05
Lead Sponsor
Alcon Research
Target Recruit Count
87
Registration Number
NCT00287521
Locations
🇺🇸

United States Investigative Sites in Texas and Other States, Fort Worth, Texas, United States

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Phase 3
Completed
Conditions
Open Angle Glaucoma
Ocular Hypertension
First Posted Date
2006-01-16
Last Posted Date
2021-02-18
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
528
Registration Number
NCT00277498
Locations
🇺🇸

Pfizer Investigational Site, Seattle, Washington, United States

Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans

Not Applicable
Withdrawn
Conditions
Glaucoma
Interventions
Device: Laser Doppler flowmetry
Device: Goldmann applanation tonometer
Procedure: Suction cup method
First Posted Date
2006-01-12
Last Posted Date
2014-11-21
Lead Sponsor
Medical University of Vienna
Registration Number
NCT00275756
Locations
🇦🇹

Department of Clinical Pharmacology, Vienna, Austria

Assessing Cosopt Switch Patients

Phase 4
Completed
Conditions
Ocular Hypertension
Open-Angle Glaucoma
Exfoliation Syndrome
Glaucoma, Pigmentary
First Posted Date
2006-01-09
Last Posted Date
2008-11-19
Lead Sponsor
Pharmaceutical Research Network
Target Recruit Count
60
Registration Number
NCT00273442
Locations
🇺🇸

Little Rock Eye Clinic, Little Rock, Arkansas, United States

🇺🇸

Omni Eye Services, Atlanta, Georgia, United States

🇺🇸

Glaucoma Consultants & Center for Eye Research, Mt. Pleasant, South Carolina, United States

and more 2 locations

Cosopt Versus Xalatan

Phase 4
Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
First Posted Date
2006-01-09
Last Posted Date
2007-01-09
Lead Sponsor
Pharmaceutical Research Network
Registration Number
NCT00273429
Locations
🇺🇸

Midwest Eye Center SC, Bourbonnais, Illinois, United States

🇺🇸

Central Florida Eye Associates, Lakeland, Florida, United States

Cosopt Versus Xalacom

Phase 4
Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
First Posted Date
2006-01-09
Last Posted Date
2008-11-19
Lead Sponsor
Pharmaceutical Research Network
Target Recruit Count
33
Registration Number
NCT00273481
Locations
🇨🇦

Lawson Health Research Insitute, London, Ontario, Canada

🇸🇮

University Eye Clinic, Ljubljana, Slovenia

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

Phase 3
Completed
Conditions
Glaucoma, Open-Angle
Ocular Hypertension
First Posted Date
2005-09-12
Last Posted Date
2021-02-21
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
500
Registration Number
NCT00159653
Locations
🇨🇦

Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada

Comparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)

Phase 3
Completed
Conditions
Ocular Hypertension
Glaucoma
First Posted Date
2005-04-13
Last Posted Date
2015-05-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
330
Registration Number
NCT00108017

Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
Glaucoma
Ocular Hypertension
Interventions
First Posted Date
2003-05-30
Last Posted Date
2016-11-18
Lead Sponsor
Alcon Research
Target Recruit Count
105
Registration Number
NCT00061542
Locations
🇺🇸

Alcon Call Center, Fort Worth, Texas, United States

Prevention of Esophageal Varices by Beta-Adrenergic Blockers

Phase 3
Completed
Conditions
Liver Cirrhosis
Esophageal and Gastric Varices
Portal Hypertension
Interventions
Drug: Placebo
First Posted Date
2000-10-06
Last Posted Date
2017-06-01
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
213
Registration Number
NCT00006398
Locations
🇬🇧

Royal Free Hospital, Hampstead, London, United Kingdom

🇺🇸

The Faulkner Hospital, Boston, Massachusetts, United States

🇪🇸

Hospital Clinic I Provincial de Barcelona, Barcelona, Catalonia, Spain

and more 2 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy